Evidence map›Paper›PMID 37665476›Full record

ArticleEJNMMI physics2023

Individualisation of radiation protection recommendations for patients treated with [

Teresa Monserrat Fuertes, Borja Santos Zorrozua, Emilia Rodeño Ortiz de Zarate, Miguel Ángel Peinado Montes, Carmen Vigil Díaz, Pablo Mínguez Gabiña

Open access · goldAbstract read
In one paragraph

Article in EJNMMI physics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Teresa Monserrat FuertesDepartment of Medical Physics and Radiation Protection, Central University Hospital of Asturias, Oviedo, Spain.
Borja Santos ZorrozuaScientific Coordination Unit, Biocruces Bizkaia Health Research Institute, Gurutzeta-Cruces University Hospital, Barakaldo, Spain.
Emilia Rodeño Ortiz de ZarateDepartment of Nuclear Medicine, Biocruces Bizkaia Health Research Institute, Gurutzeta-Cruces University Hospital, Barakaldo, Spain.
Miguel Ángel Peinado MontesDepartment of Medical Physics and Radiation Protection, Central University Hospital of Asturias, Oviedo, Spain.
Carmen Vigil DíazDepartment of Nuclear Medicine, Central University Hospital of Asturias, Oviedo, Spain.
Pablo Mínguez GabiñaDepartment of Medical Physics and Radiation Protection, Biocruces Bizkaia Health Research Institute, Gurutzeta-Cruces University Hospital, Gurutzeta Plaza Z/G, 48903, Barakaldo, Bizkaia, Spain. pablo.minguezgabina@osakidetza.eus.ORCID http://orcid.org/0000-0003-1384-474X
BioCruces Health research Institute · ESHospital Universitario Central de Asturias · ESUniversity of the Basque Country · ES

Funding

Eusko Jaurlaritza 2020111042
6 · The paper itself

Abstract

backgroundAs for any other nuclear medicine treatment, patients treated with [

methodsThe whole-body time-activity curve was calculated for 20 patients from dose-rate measurements performed during the first week post-administration. An effective decay time [Formula: see text] was calculated from a mono-exponential fit performed with the 6 h and 24 h measurements and compared with the effective decay time [Formula: see text] obtained from the mono-exponential fit performed with the 24 h, 48 h and 168 h measurements. The differences between them were calculated and the 95th percentile of these differences was used as a correction factor for [Formula: see text]. A modified effective decay [Formula: see text] was obtained by adding the correction factor to [Formula: see text] and the restriction periods for each patient was calculated. The whole body activity washout between the first and the fourth treatment cycles of 16 patients was also compared.

resultsThe comparison of the whole-body activity curves between the first and the fourth cycle of the treatment for 16 patients would indicate that the recommendations on radiation protection determined from the first cycle could reasonably be used for the remaining cycles in most patients. The values of [Formula: see text] and [Formula: see text] obtained for the 20 patients were significantly different. The 95th percentile of the differences between [Formula: see text] and [Formula: see text] was 46 h, which is thus the time to be added to [Formula: see text] so as to determine the restriction periods.

conclusionsThe proposed method makes it possible to calculate the restriction periods for patients treated with [

Indexed as

[177Lu]Lu-DOTA-TATE treatmentsIndividualized recommendationsRadiation protection

Identifiers

PMID37665476
PMCPMC10477145
OpenAlexW4386407620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.